This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy and Cookie Notice.

Skip to main content

Search Results

Featured Stories

Toggle

Working hard to keep medicines moving

As the COVID-19 situation evolves globally, we are striving to provide an uninterrupted supply of medicines to the 200 million patients that we serve around the world. The global emergency...

3 tips to stay focused at work during uncertain times

For many of us, the coronavirus pandemic has had a huge impact on our work, family and social lives. At Teva, thousands of colleagues are now working from home and have had the reassuring familiari...

Teva Announces Virtual 2020 Annual Meeting of Shareholders

TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders,...

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab

TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY ® (fremanezumab) and the societal and economic...

Teva presenterà nuove analisi su AJOVY® (fremanezumab) e i dati più recenti su COPAXONE® (glatiramer acet

TEL AVIV, Israele--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE e TASE: TEVA) oggi ha annunciato la presentazione di nuovi dati su AJOVY ® (fremanezumab) e sull'impatto...

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio

TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY ® (fremanezumab) and the burden of migraine in Europe will be...